Vitamin D Supplementation in Older Women (VIDOS)
Determination of RDA for Vitamin D in Caucasian and African American Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence of osteoporosis is high in the United States, with about 10 million people over the age of 50 already having the disease and another 34 million at risk for developing it. Development of low-cost and effective strategies is important for preventing osteoporosis and reducing osteoporotic fractures. A simple inexpensive strategy to prevent osteoporosis is adequate nutrition with calcium and vitamin D. Serum 25OHD (25-hydroxyvitamin D) is now accepted as the objective measure of vitamin D nutrition. There is a growing understanding that serum 25OHD concentrations of at least 30-32 ng/ml are needed for optimal bone health at which serum parathyroid hormone (PTH) concentrations reach a minimum.
There are no systematic prospective dose response studies aimed at determining the optimum amount of vitamin D intake required to maintain optimum serum 25OHD levels in the population which will help in determining the estimated average requirement (EAR) and recommended dietary requirement (RDA) for vitamin D. More work to determine the RDA for vitamin D has been recommended by the Panel on Calcium and Related Nutrients of the Food and Nutrition Board. This study is aimed at filling the information gap by concentrating on the high risk group of postmenopausal women. We are testing the theory that increasing serum 25OHD to a level greater than 30 ng/ml will reduce serum PTH in the high risk group of vitamin D insufficient postmenopausal women with an adequate intake of calcium. We also believe that the dose of vitamin D that will achieve this level is approximately 4400IU per day, which is well above the suggested adequate intake of 400-600 ID recommended for the elderly.
In a one year double blind, randomized prospective clinical trial, we will examine the dose response effect of supplementation with different doses of vitamin D3 (400, 800, 1600, 2400, 3200, 4000, 4800IU/day) on the primary outcomes of serum 25OHD and PTH in 160 postmenopausal Caucasian and 160 African American women who have inadequate vitamin D levels in winter. We expect that the results from this study will add useful and important information about the RDA for vitamin D for postmenopausal women who are more susceptible to osteoporosis. The results from this study will also help in designing future clinical trials to study the effect of vitamin D, for example in preventing fractures, falls, cancer.
The main objective of the current proposal is to study the effect of increasing doses of vitamin D3 in the high risk group of postmenopausal Caucasian and African American women with hypovitaminosis D (serum 25OHD <20 ng/ml) in winter in presence of sufficient calcium intake, in order to determine the Estimated Average Requirement (EAR) that covers 50% and the Recommended Daily allowance (RDA) covers 97.5% of population for vitamin D. We will use a serum 25OHD concentration equal >30 ng/ml and normalization of serum PTH as indicators of adequacy. We expect that the results from this proposal will add important information helpful in designing future larger clinical trials to determine the recommended dietary allowance (RDA) for vitamin D in other ethnic groups and designing clinical trials on the effect of vitamin D on falls and fractures.
We hypothesize that increasing serum 25OHD to a level greater than 30 ng/ml with vitamin D supplements in 97 percent of the study subjects will reduce serum PTH and bone markers to premenopausal range. We postulate that the RDA of vitamin D that will achieve a serum 25OHD of ≥ 30 ng/ml in 97.5% of women during winter is approximately 4400 IU/d and the EAR dose of vitamin D is between 800-1000 IU.
The specific aims of the proposal are,
- To examine the dose response effect of vitamin D3, 400, 800, 1600, 2400, 3200, 4000, and 4800 IU /d in postmenopausal Caucasian and African American women with hypovitaminosis D (serum 25OHD equal <20 ng/ml) in winter plus an adequate calcium intake compared to a calcium control group, on serum 25OHD and PTH levels, which constitute our primary outcome measures.
- To determine the EAR and RDA for postmenopausal women by establishing the dose of vitamin D3 that will increase serum 25OHD above 30 ng/ml in 97.5% of study subjects in winter and reduce serum PTH to the normal premenopausal range.
- To study the dose response effect of vitamin D3 on calcium absorption, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) serum calcium, serum bone markers, bone mineral density (BMD) and falls (only in elderly) (the secondary outcome measures)
- To establish the long term safety of these doses relating to hypercalcemia and hypercalciuria
Progress: Caucasian enrollment completed July 2008; African American enrollment completed May 2009
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Creighton University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 7 years post-menopause
- Serum 25OHD level 5 ng/ml to 20 ng/ml
- BMI less than or equal to 40 kg/m2
- Willing to discontinue multivitamins that contain vitamin D during the study
Exclusion Criteria:
- Cancer (except basal cell carcinoma) or terminal illness
- Previous hip fracture
- Hemiplegia (paralysis of one side of the body)
- Uncontrolled type I diabetes or fasting blood sugar greater than 140 mg in type II
- Kidney stones more than twice in a lifetime
- Chronic renal failure
- Evidence of chronic liver disease, including alcoholism
- Physical conditions such as severe osteoarthritis, rheumatoid arthritis, heart failure severe enough to prevent reasonable physical activity
- Previous treatment with bisphosphonates (more that 3 months), PTH or PTH derivatives, (e.g. Teriparatide or Fluoride) in the last 6 months
- Previous treatment within the last 6 months with calcitonin or estrogen
- Chronic high dose corticosteroid therapy (more than 10 mg per day) for over 6 months and not within the last 6 months
- Anticonvulsant therapy
- High dose thiazide therapy (more than 37.5 mg)
- 24 hour urine calcium greater than 290 mg on 2 baseline tests
- Serum calcium exceeding upper normal limit on 2 baseline tests
- Bone Mineral Density T-score less than -3.0 for spine or hip
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: vitamin D3 400 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Experimental: vitamin D3 800 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Experimental: vitamin D3 1600 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Experimental: vitamin D3 2400 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Experimental: vitamin D3 3200 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Experimental: vitamin D3 4000 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Experimental: vitamin D3 4800 IU daily
|
Orally for one year
Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Other Names:
|
|
Placebo Comparator: placebo
matched to vitamin D tablet
|
Orally for one year
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in Serum 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) levels
Time Frame: Baseline, 6months,12 months
|
Baseline, 6months,12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calcium absorption
Time Frame: Baseline and 12 months
|
100mg calcium+ calcium45
|
Baseline and 12 months
|
|
Serum/urine calcium
Time Frame: Baseline and every 3 months
|
Baseline and every 3 months
|
|
|
Bone markers
Time Frame: Baseline, and 12 months
|
Baseline, and 12 months
|
|
|
Bone density
Time Frame: Baseline and 12 months
|
spine,hip,total body,lateral
|
Baseline and 12 months
|
|
Muscle strength
Time Frame: Baseline,6 months,12 months
|
leg strength( Cybex),timed up and go,hand grip,chair stand,gait speed,quiet stance,postural stability( biodex),standing balance
|
Baseline,6 months,12 months
|
|
Falls
Time Frame: Baseline and every 3 months
|
questionnaire
|
Baseline and every 3 months
|
|
Pulmonary function studies
Time Frame: baseline and final test
|
FEV1
|
baseline and final test
|
|
Genotyping
Time Frame: one time
|
one time
|
|
|
Molecular studies of peripheral leucocytes
Time Frame: baseline and final test
|
baseline and final test
|
|
|
Adult Depression Score
Time Frame: baseline and 12 months
|
questionnaire
|
baseline and 12 months
|
|
Physical Activity Scale form ( PASE)
Time Frame: baseline,6 months,12 months
|
questionnaire
|
baseline,6 months,12 months
|
|
sun exposure
Time Frame: baseline and every 3 months
|
sun exposure form and skin color evaluation by a reflective meter (SmartProbe)
|
baseline and every 3 months
|
|
Basic metabolic panel
Time Frame: baseline and every 3 months
|
baseline and every 3 months
|
|
|
serum 1,25 dihydroxyvitamin D
Time Frame: baseline and 12 months
|
baseline and 12 months
|
|
|
quality of life
Time Frame: baseline and 12 months
|
questionnaire
|
baseline and 12 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24. doi: 10.1210/jc.2004-2364. Epub 2005 Mar 29.
- Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006 Sep;84(3):602-9. doi: 10.1093/ajcn/84.3.602.
- Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res. 1998 Mar;13(3):475-82. doi: 10.1359/jbmr.1998.13.3.475.
- Smith LM, Gallagher JC. Effect of vitamin D supplementation on total and free 25 hydroxyvitamin D and parathyroid hormone. An analysis of two randomized controlled trials. J Intern Med. 2019 Dec;286(6):651-659. doi: 10.1111/joim.12950. Epub 2019 Jul 29.
- Smith LM, Gallagher JC, Kaufmann M, Jones G. Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women: a randomized controlled trial. J Intern Med. 2018 Dec;284(6):685-693. doi: 10.1111/joim.12825. Epub 2018 Sep 17.
- Gallagher JC, Smith LM, Yalamanchili V. Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women. Menopause. 2014 Nov;21(11):1173-80. doi: 10.1097/GME.0000000000000270.
- Gallagher JC, Jindal PS, Smith LM. Vitamin D does not increase calcium absorption in young women: a randomized clinical trial. J Bone Miner Res. 2014;29(5):1081-7. doi: 10.1002/jbmr.2121.
- Gallagher JC, Peacock M, Yalamanchili V, Smith LM. Effects of vitamin D supplementation in older African American women. J Clin Endocrinol Metab. 2013 Mar;98(3):1137-46. doi: 10.1210/jc.2012-3106. Epub 2013 Feb 5.
- Gallagher JC, Sai A, Templin T 2nd, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):425-37. doi: 10.7326/0003-4819-156-6-201203200-00005. Erratum In: Ann Intern Med. 2012 May 1;156(9):672.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG0081
- 1R01AG028168-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.